Pablo Jose Sanchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pablo Jose Sanchez has a total of 481 co-authors. Here are the top co-authors by number of shared publications:
- Asuncion Mejias
Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
8 shared publications - Jacqueline Magers
Department of Pharmacy, Nationwide Children’s Hospital, Columbus, USA
6 shared publications Joseph B. Cantey
University of Texas Southwestern Medical Center, Dallas, TX; University of Texas Health Science Center at San Antonio, San Antonio, TX
6 shared publications- Octavio Ramilo
Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
6 shared publications - Pavel Prusakov
Department of Pharmacy, Nationwide Children’s Hospital, Columbus, USA
6 shared publications - Abbot R. Laptook
Department of Pediatrics, Women and Infants Hospital, Brown University, Providence, RI
5 shared publications
Latest Publications
- 26 August 2026
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 39 (5) , 458-466
Management of neonates born to mothers with reactive serologic tests for syphilis
Purpose of review: The dramatic resurgence of maternal and congenital syphilis in the United States highlights the need for their optimal management as syphilis in pregnancy can result in substantial neonatal morbidity and mortality. This review summarizes current epidemiology and discusses guidance on the management of neonates born to mothers with reactive serologic tests for syphilis. Recent findings: Timely communication with local health department professionals is essential for optimal management of mothers with reactive serologic tests for syphilis and their neonates. Knowledge of maternal syphilis treatment history by partnering with local jurisdictions can circumvent much of the incertitude surrounding neonatal management. All neonates born to mothers with reactive serologic tests for syphilis should be tested using a nontreponemal (‘lipoidal antigen’) test. However, a reactive test may only indicate maternal nontreponemal IgG antibodies that are transferred transplacentally to the fetus. Therefore, neonatal management depends on maternal history and treatment for syphilis as well as clinical, laboratory, and radiographic findings in the neonatal evaluation. Existing management algorithms are complex, highlighting the need for a more practical, yet safe, approach. Summary: A neonatal management guideline is proposed that may simplify the management of neonates born to mothers with reactive serologic tests for syphilis while advocating for expanded use of single-dose benzathine penicillin G therapy.
- 26 August 2026
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 39 (5) , 458-466
Management of neonates born to mothers with reactive serologic tests for syphilis
Purpose of review: The dramatic resurgence of maternal and congenital syphilis in the United States highlights the need for their optimal management as syphilis in pregnancy can result in substantial neonatal morbidity and mortality. This review summarizes current epidemiology and discusses guidance on the management of neonates born to mothers with reactive serologic tests for syphilis. Recent findings: Timely communication with local health department professionals is essential for optimal management of mothers with reactive serologic tests for syphilis and their neonates. Knowledge of maternal syphilis treatment history by partnering with local jurisdictions can circumvent much of the incertitude surrounding neonatal management. All neonates born to mothers with reactive serologic tests for syphilis should be tested using a nontreponemal (‘lipoidal antigen’) test. However, a reactive test may only indicate maternal nontreponemal IgG antibodies that are transferred transplacentally to the fetus. Therefore, neonatal management depends on maternal history and treatment for syphilis as well as clinical, laboratory, and radiographic findings in the neonatal evaluation. Existing management algorithms are complex, highlighting the need for a more practical, yet safe, approach. Summary: A neonatal management guideline is proposed that may simplify the management of neonates born to mothers with reactive serologic tests for syphilis while advocating for expanded use of single-dose benzathine penicillin G therapy.
- Open Access
- 11 August 2026
- Published by Sociedad Chilena de Pediatria in Andes Pediatrica
- Vol. 97 (4) , 730-742
Sepsis precoz en recién nacidos: recomendaciones de la Rama de Neonatología, Sociedad Chilena de Pediatría
La sepsis precoz constituye una de las principales causas de morbimortalidad en el periodo neonatal. La epidemiología y etiología han cambiado en los últimos años, influido en gran parte por la profilaxis contra Streptococcus agalactiae o Streptococcus grupo B y la emergencia de Escherichia coli como el principal agente en recién nacidos (RN) pretérmino. Desde hace varios años, se ha incorporado a la práctica clínica el Calculador de Riesgo de Sepsis Precoz, herramienta que permiten un acercamiento más estandarizado, con menores tasas de hospitalización y disminución del uso de antibióticos. Además, el uso de nuevas técnicas de laboratorio y la mejoría en la sensibilidad de los cultivos, contribuyen a un mejor diagnóstico y por ende, un tratamiento óptimo y acotado. Este artículo es una recomendación de la Rama de Neonatología de la Sociedad Chilena de Pediatría y tiene como objetivo revisar los aspectos epidemiológicos, etiológicos y factores de riesgo para sepsis precoz, incluyendo las recomendaciones de la Academia Americana de Pediatría y el Colegio Americano de Obstetricia y Ginecología publicadas en el año 2019. Se analizan las principales manifestaciones clínicas, herramientas diagnósticas y tratamiento. Considerando los elementos antes descritos y las publicaciones de los últimos años, se incorporan recomendaciones para el enfrentamiento de los recién nacidos con sospecha de sepsis precoz.
- 11 August 2026
- Published by Sociedad Chilena de Pediatria in Andes Pediatrica
- Vol. 97 (4) , 730-742
Open AccessSepsis precoz en recién nacidos: recomendaciones de la Rama de Neonatología, Sociedad Chilena de Pediatría
La sepsis precoz constituye una de las principales causas de morbimortalidad en el periodo neonatal. La epidemiología y etiología han cambiado en los últimos años, influido en gran parte por la profilaxis contra Streptococcus agalactiae o Streptococcus grupo B y la emergencia de Escherichia coli como el principal agente en recién nacidos (RN) pretérmino. Desde hace varios años, se ha incorporado a la práctica clínica el Calculador de Riesgo de Sepsis Precoz, herramienta que permiten un acercamiento más estandarizado, con menores tasas de hospitalización y disminución del uso de antibióticos. Además, el uso de nuevas técnicas de laboratorio y la mejoría en la sensibilidad de los cultivos, contribuyen a un mejor diagnóstico y por ende, un tratamiento óptimo y acotado. Este artículo es una recomendación de la Rama de Neonatología de la Sociedad Chilena de Pediatría y tiene como objetivo revisar los aspectos epidemiológicos, etiológicos y factores de riesgo para sepsis precoz, incluyendo las recomendaciones de la Academia Americana de Pediatría y el Colegio Americano de Obstetricia y Ginecología publicadas en el año 2019. Se analizan las principales manifestaciones clínicas, herramientas diagnósticas y tratamiento. Considerando los elementos antes descritos y las publicaciones de los últimos años, se incorporan recomendaciones para el enfrentamiento de los recién nacidos con sospecha de sepsis precoz.
- Open Access
- 4 June 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (4) , 101567
Neonatal bacterial meningitis: the elusive search for markers of severity
- 4 June 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (4) , 101567
Open AccessNeonatal bacterial meningitis: the elusive search for markers of severity
- Open Access
- 29 April 2026
- Published by Springer Nature in Journal of Perinatology
- Vol. 46 (5) , 754-760
Urinary tract infection in the neonatal intensive care unit
Objective: To determine adherence and safety of a diagnostic (culture, urinalysis) and therapeutic (5-day antibiotic course with a time-out) guideline for urinary tract infection (UTI) in the Neonatal Intensive Care Unit Study design: Prospective surveillance of non-bacteremic UTIs from 11/2020-12/2022. Safety outcomes were defined by re-initiation of antibiotics within 7 days for a subsequent UTI due to the same organism and overall and UTI-related mortality. Results: 77 infants received treatment for 93 UTIs with 77% (72/93) adherence to diagnostic criteria; 90% (82/91) of infants received ≤6 days of definitive treatment (median [IQR] antibiotic duration 5 [5–6] days). Antibiotics were restarted within 7 days for a recurrent (same organism) UTI in 1/91 (1%) UTIs. Mortality was 4% (4/93); none were due to UTI. Conclusion: Adherence to diagnostic UTI criteria was 77%. 90% of infants received short course treatment that was associated with a 1% failure rate. No safety concern was identified.
- 29 April 2026
- Published by Springer Nature in Journal of Perinatology
- Vol. 46 (5) , 754-760
Open AccessUrinary tract infection in the neonatal intensive care unit
Objective: To determine adherence and safety of a diagnostic (culture, urinalysis) and therapeutic (5-day antibiotic course with a time-out) guideline for urinary tract infection (UTI) in the Neonatal Intensive Care Unit Study design: Prospective surveillance of non-bacteremic UTIs from 11/2020-12/2022. Safety outcomes were defined by re-initiation of antibiotics within 7 days for a subsequent UTI due to the same organism and overall and UTI-related mortality. Results: 77 infants received treatment for 93 UTIs with 77% (72/93) adherence to diagnostic criteria; 90% (82/91) of infants received ≤6 days of definitive treatment (median [IQR] antibiotic duration 5 [5–6] days). Antibiotics were restarted within 7 days for a recurrent (same organism) UTI in 1/91 (1%) UTIs. Mortality was 4% (4/93); none were due to UTI. Conclusion: Adherence to diagnostic UTI criteria was 77%. 90% of infants received short course treatment that was associated with a 1% failure rate. No safety concern was identified.
- 7 April 2026
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 53 (5) , 316-318
Pitfalls in the Serologic Diagnosis of Maternal Syphilis: A Case Series
Pregnancy is associated with false-positive treponemal and nontreponemal screening test results. We present 5 pregnant women who had reactive treponemal screening and nontreponemal test results but nonreactive Treponema pallidum– particle agglutination test result. Reliance on treponemal screening tests may result in misdiagnosis and unnecessary treatment, unless a specific treponemal test is performed.
- 7 April 2026
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 53 (5) , 316-318
Pitfalls in the Serologic Diagnosis of Maternal Syphilis: A Case Series
Pregnancy is associated with false-positive treponemal and nontreponemal screening test results. We present 5 pregnant women who had reactive treponemal screening and nontreponemal test results but nonreactive Treponema pallidum– particle agglutination test result. Reliance on treponemal screening tests may result in misdiagnosis and unnecessary treatment, unless a specific treponemal test is performed.
- 10 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic Study
Background: Ganciclovir remains the primary therapeutic for cytomegalovirus (CMV) infections in early infancy, but its pharmacokinetics and dosing in very preterm infants with end-organ CMV disease have not been fully evaluated. Methods: Premature infants with confirmed CMV infection and receiving ganciclovir as standard of care were enrolled into a pharmacokinetic (PK) sampling study. All infants were 500 g at enrollment. Plasma for ganciclovir quantitation was collected at steady state at 0, 1, 2–3, 5–7, and 10–12 hours after the dose. Specimens were shipped and analyzed, and PK parameters were calculated in real time. Noncompartmental and modeling approaches were used for analysis. Results: Eighteen infants were enrolled; their mean gestational age at delivery was 26.7 weeks, and their mean age and weight at enrollment were 42 days and 1519.0 g, respectively. PK assessments were completed in 17. The geometric mean dose and resulting 12-hour area under the curve were 5.19 mg/kg and 52.7 mg · h/L, respectively. A total of 85 ganciclovir concentration-time data points were available for modeling. A 1-compartment power covariate model with weight and serum creatinine on clearance and weight on distribution volume was used. Noncompartmental and modeled PK parameters were similar. Conclusions: These are the first intravenous ganciclovir population PK data with covariate assessments in premature infants being treated for CMV disease. Results suggest an intravenous dose of 5 mg/kg every 12 hours may be an appropriate starting regimen in of premature infants with congenital CMV. Additional data are needed in this and other populations to better define optimal ganciclovir exposure targets.
- 10 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic Study
Background: Ganciclovir remains the primary therapeutic for cytomegalovirus (CMV) infections in early infancy, but its pharmacokinetics and dosing in very preterm infants with end-organ CMV disease have not been fully evaluated. Methods: Premature infants with confirmed CMV infection and receiving ganciclovir as standard of care were enrolled into a pharmacokinetic (PK) sampling study. All infants were 500 g at enrollment. Plasma for ganciclovir quantitation was collected at steady state at 0, 1, 2–3, 5–7, and 10–12 hours after the dose. Specimens were shipped and analyzed, and PK parameters were calculated in real time. Noncompartmental and modeling approaches were used for analysis. Results: Eighteen infants were enrolled; their mean gestational age at delivery was 26.7 weeks, and their mean age and weight at enrollment were 42 days and 1519.0 g, respectively. PK assessments were completed in 17. The geometric mean dose and resulting 12-hour area under the curve were 5.19 mg/kg and 52.7 mg · h/L, respectively. A total of 85 ganciclovir concentration-time data points were available for modeling. A 1-compartment power covariate model with weight and serum creatinine on clearance and weight on distribution volume was used. Noncompartmental and modeled PK parameters were similar. Conclusions: These are the first intravenous ganciclovir population PK data with covariate assessments in premature infants being treated for CMV disease. Results suggest an intravenous dose of 5 mg/kg every 12 hours may be an appropriate starting regimen in of premature infants with congenital CMV. Additional data are needed in this and other populations to better define optimal ganciclovir exposure targets.
- 8 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (6) , e738-e740
Role of Viral Codetections in Young Children With Respiratory Syncytial Virus Infection
- 8 August 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (6) , e738-e740
Role of Viral Codetections in Young Children With Respiratory Syncytial Virus Infection
- 23 July 2025
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 38 (5) , 443-449
Management of neonates born to mothers with active genital herpes simplex virus infection: an alternative approach
Purpose of review: Although considered a rare disease, neonatal HSV infection represents a disease in urgent need of preventive strategies, as it results in substantial neonatal morbidity and mortality. This review summarizes its current epidemiology and discusses guidances on the management of the asymptomatic neonate born to mothers with active genital HSV infection. Recent findings: Timely detection and early high-dose acyclovir treatment of neonatal HSV infection decreases mortality. All neonates born to mothers with active genital HSV infection in the third trimester or at delivery should be tested for HSV infection. The newborn management has depended on whether the mother has experienced a primary or recurrent genital HSV infection based on maternal serologic testing and PCR testing of the genital lesion. An alternative strategy on neonatal management is proposed that is based on type of maternal HSV infection and perinatal risk factors. Summary: The incidence of neonatal HSV infection is increasing with more infections due to HSV-1 than HSV-2. Guidances addressing management of the asymptomatic newborn exposed to active maternal genital HSV infection are discussed.
- 23 July 2025
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 38 (5) , 443-449
Management of neonates born to mothers with active genital herpes simplex virus infection: an alternative approach
Purpose of review: Although considered a rare disease, neonatal HSV infection represents a disease in urgent need of preventive strategies, as it results in substantial neonatal morbidity and mortality. This review summarizes its current epidemiology and discusses guidances on the management of the asymptomatic neonate born to mothers with active genital HSV infection. Recent findings: Timely detection and early high-dose acyclovir treatment of neonatal HSV infection decreases mortality. All neonates born to mothers with active genital HSV infection in the third trimester or at delivery should be tested for HSV infection. The newborn management has depended on whether the mother has experienced a primary or recurrent genital HSV infection based on maternal serologic testing and PCR testing of the genital lesion. An alternative strategy on neonatal management is proposed that is based on type of maternal HSV infection and perinatal risk factors. Summary: The incidence of neonatal HSV infection is increasing with more infections due to HSV-1 than HSV-2. Guidances addressing management of the asymptomatic newborn exposed to active maternal genital HSV infection are discussed.
- 16 July 2025
- Published by Elsevier in Clinics in Perinatology
- Vol. 52 (3) , 523-538
The Case for Universal Newborn Congenital Cytomegalovirus Screening
- 16 July 2025
- Published by Elsevier in Clinics in Perinatology
- Vol. 52 (3) , 523-538
The Case for Universal Newborn Congenital Cytomegalovirus Screening
- Open Access
- 16 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
SARS-CoV-2 induced immune perturbations in infants vary with disease severity and differ from adults’ responses
Differences in immune profiles of children and adults with COVID-19 have been previously described. However, no systematic studies have been reported from infants hospitalized with severe disease. We applied a multidimensional approach to decipher the immune responses of SARS-CoV-2 infected infants (n = 26; 10 subacute, 11 moderate and 5 severe disease; median age = 1.6 months) and matched controls (n = 14; median age = 2 months). Single cell (scRNA-seq) profiling of PBMCs revealed substantial alterations in cell composition in SARS-CoV-2 infected infants; with most cell-types switching to an interferon-stimulated gene (ISGhi) state including: (i) CD14+ monocytes co-expressing ISGs and inflammasome-related molecules, (ii) ISGhi naive CD4+ T cells, (iii) ISGhi proliferating cytotoxic CD8+ T cells, and (iv) ISGhi naive and transitional B cells. We observe increased serum concentrations of both interferons and inflammatory cytokines in infected infants. Antibody responses to SARS-CoV-2 are also consistently detected in the absence of anti-IFN autoantibodies. Compared with infected adults, infants display a similar ISG signature in monocytes but a markedly enhanced ISG signature in T and B cells. These findings provide insights into the distinct immune responses to SARS-CoV-2 in the first year of life and underscore the importance of further defining the unique features of early life immunity.
- 16 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Open AccessSARS-CoV-2 induced immune perturbations in infants vary with disease severity and differ from adults’ responses
Differences in immune profiles of children and adults with COVID-19 have been previously described. However, no systematic studies have been reported from infants hospitalized with severe disease. We applied a multidimensional approach to decipher the immune responses of SARS-CoV-2 infected infants (n = 26; 10 subacute, 11 moderate and 5 severe disease; median age = 1.6 months) and matched controls (n = 14; median age = 2 months). Single cell (scRNA-seq) profiling of PBMCs revealed substantial alterations in cell composition in SARS-CoV-2 infected infants; with most cell-types switching to an interferon-stimulated gene (ISGhi) state including: (i) CD14+ monocytes co-expressing ISGs and inflammasome-related molecules, (ii) ISGhi naive CD4+ T cells, (iii) ISGhi proliferating cytotoxic CD8+ T cells, and (iv) ISGhi naive and transitional B cells. We observe increased serum concentrations of both interferons and inflammatory cytokines in infected infants. Antibody responses to SARS-CoV-2 are also consistently detected in the absence of anti-IFN autoantibodies. Compared with infected adults, infants display a similar ISG signature in monocytes but a markedly enhanced ISG signature in T and B cells. These findings provide insights into the distinct immune responses to SARS-CoV-2 in the first year of life and underscore the importance of further defining the unique features of early life immunity.